RxDoctor Payments Data

Courtland Hunter, APRN

Family · Monticello, ARNPI 1821731498

Payments from drug & device makers

$358in general payments, 2019–2025

Across 15 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$135
  • Merck$36
  • Exact Sciences$34
  • Lundbeck LLC$20
  • AstraZeneca$19
  • AbbVie$19
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$24268%
  • Education$11632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$358 in reported general payments places this provider in the 45th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,884
Medicare patients
90
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$12,696
Albuterol Sulfate HfaAlbuterol Sulfate43$1,216
Gabapentin81$1,197
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide16$743
Methylprednisolone61$570
Potassium Chloride22$499
Omeprazole24$492
Doxycycline Hyclate37$395
Celecoxib11$362
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$361
Atorvastatin Calcium51$354
Fluticasone Propionate31$350
Levothyroxine Sodium26$306
Losartan Potassium47$286
Duloxetine Hcl12$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$19$12,69616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,103 family providers in Arkansas.

Other family in Monticello

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →